6-K: Supernova Phase Iii Trial of Sipavibart Long-Acting Antibody Met Primary Endpoints in Preventing Covid-19 in Immunocompromised Patient Population
6-K: Transaction by Person Discharging Managerial Responsibilities
6-K: AstraZeneca Completes Equity Investment Agreement with Cellectis
6-K: Calquence Combination Improved PFS in 1L MCL
6-K: Total Voting Rights
6-K: Truqap Recommended for EU Breast Cancer Approval
6-K: Enhertu Improved PFS in HER2-Low and Ultralow
6-K: Q1 2024 Results
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | DFAN14A: Definitive additional proxy soliciting materials filed by non-management
ASTRAZENECA | F-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ASTRAZENECA | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No Data